Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
772.700.06%
QQQ
717.030.09%
BTC/USD
81062.500.2628%
DIA
536.820.02%
GLD
410.870.16%
TLT
82.140.09%

Collegium Pharmaceutical Inc

COLLNASDAQ
Trade with Public
Trade with Public
$23.70
-0.60-2.47%
At close: Sep 3, 5:00 PM EST
$23.70
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Collegium Pharmaceutical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Collegium Pharmaceutical (COLL).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

5Buy
1Hold
Consensus RatingBuy# Analysts6Avg. Consensus PT$47Upside to Avg. PT+98.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 19, 2026BarclaysGlen SantangeloPT CutOverweight$56→$48
Aug 7, 2026Piper SandlerDavid AmsellemPT CutNeutral$45→$43
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.
Benzinga Newsdesk

PRO
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Collegium Pharmaceutical, Maintains $60 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and maintains $60 price target.
Benzinga Newsdesk

Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings)

Benzinga Insights

PRO
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $54

Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $54.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved